US medical devices industry saw a drop of 11.01% in overall deal activity during September 2022, when compared with the last 12-month average, led by CVS Health’s $8bn acquisition of Signify Health, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

A total of 97 deals worth $10.3bn were announced in September 2022, compared with the 12-month average of 109 deals.

venture financing was the leading category in the month in terms of volume with 74 deals, which accounted for 76.3% of all deals.

In second place was M&A with 18 deals, followed by private equity with five transactions, respectively accounting for 18.6% and 5.2% of overall deal activity in the US technology industry during the month.

In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $9.07bn, while venture financing and private equity deals totalled $760.5m and $488m, respectively.

US medical devices industry deals in September 2022: Top deals

The top five medical devices industry deals accounted for 91.6% of the overall value during September 2022.

The combined value of the top five medical devices deals stood at $9.44bn, against the overall value of $10.3bn recorded for the month.

The top five medical devices industry deals of September 2022 tracked by GlobalData were:

1) CVS Health’s $8bn acquisition deal with Signify Health

2) The $875m acquisition of Rx Savings Solutions by McKesson

3) Orbimed Advisors’s $250m private equity deal with Adaptive Biotechnologies

4) The $165m private equity of Theragun by HartBeat Ventures, North Castle Partners and Rx3 Ventures

5) Halma’s $154.02m acquisition deal with IZI Medical Products